Bivalent HIV-1 fusion inhibitors based on peptidomimetics

Dimerized fusion inhibitor peptides targeting the HR1–HR2 interaction of SARS-CoV-2

“…2a). 8,9,15,[20][21][22][23] In the past two decades, we have been developing anti-HIV-1 agents including fusion inhibitors, [24][25][26][27][28] and have found that the C-terminal dimer of HIV-1 HR2 region (C34) based peptides demonstrated two orders of magnitude higher potency than the parent monomeric peptides (Fig. 2b).…”